产品
编 号：F044432
分子式：C9H14F2N2O5
分子量：268.21
分子式：C9H14F2N2O5
分子量：268.21
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 1141397-80-9
产品详情
生物活性：
Cedazuridine (E7727) (Compound 7a) is an orally active cytidine deaminase (CDA) inhibitor with an IC50 value of 0.4 μM. Cedazuridine can be used for cancer research.
体内研究：
Cedazuridine (3 mg/kg; p.o.; daily for 7 days) in combination with 2.5 mg/kg AZA shows tumor regression in mice MOLM-13 CDX and PDX models.Animal Model:Female NSGS mice, 6–8 weeks old, human cell line-derived (CDX) and primary patient-derived xenograft (PDX) models
Dosage:3 mg/kg
Administration:Oral administration, in combination with 2.5 mg/kg AZA, daily for 7 days
Result:Led to reduction of leukemic expansion in combination with AZA in a cell line-derived xenograft transplantation, and exhibited preliminary safety and efcacy in a primary AML PDX model.
Animal Model:NSGS male mice
Dosage:1, 3, 10 and 30 mg/kg
Administration:Oral, in combination with 2.5 mg/kg AZA (Pharmacokinetic Studies)
Result:Dose-dependently increased the AUC of oral AZA and in comparison to dosing of standard i.p. AZA.
体外研究：
Cedazuridine (Compound 7a) exhibits superior acid stability.Cedazuridine (0-10 μM; 72 h) does not enhance effects of AZA (5-Azacytidine, HY-10586) in growth inhibition of AML cell lines.
Cedazuridine (E7727) (Compound 7a) is an orally active cytidine deaminase (CDA) inhibitor with an IC50 value of 0.4 μM. Cedazuridine can be used for cancer research.
体内研究：
Cedazuridine (3 mg/kg; p.o.; daily for 7 days) in combination with 2.5 mg/kg AZA shows tumor regression in mice MOLM-13 CDX and PDX models.Animal Model:Female NSGS mice, 6–8 weeks old, human cell line-derived (CDX) and primary patient-derived xenograft (PDX) models
Dosage:3 mg/kg
Administration:Oral administration, in combination with 2.5 mg/kg AZA, daily for 7 days
Result:Led to reduction of leukemic expansion in combination with AZA in a cell line-derived xenograft transplantation, and exhibited preliminary safety and efcacy in a primary AML PDX model.
Animal Model:NSGS male mice
Dosage:1, 3, 10 and 30 mg/kg
Administration:Oral, in combination with 2.5 mg/kg AZA (Pharmacokinetic Studies)
Result:Dose-dependently increased the AUC of oral AZA and in comparison to dosing of standard i.p. AZA.
体外研究：
Cedazuridine (Compound 7a) exhibits superior acid stability.Cedazuridine (0-10 μM; 72 h) does not enhance effects of AZA (5-Azacytidine, HY-10586) in growth inhibition of AML cell lines.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备